JP2018520667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520667A5 JP2018520667A5 JP2017564407A JP2017564407A JP2018520667A5 JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5 JP 2017564407 A JP2017564407 A JP 2017564407A JP 2017564407 A JP2017564407 A JP 2017564407A JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- heavy chain
- light chain
- variable region
- human antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078441A JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173330P | 2015-06-09 | 2015-06-09 | |
| US62/173,330 | 2015-06-09 | ||
| PCT/US2016/036735 WO2016201124A2 (en) | 2015-06-09 | 2016-06-09 | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Division JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520667A JP2018520667A (ja) | 2018-08-02 |
| JP2018520667A5 true JP2018520667A5 (https=) | 2020-05-28 |
| JP7000162B2 JP7000162B2 (ja) | 2022-02-10 |
Family
ID=57504187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564407A Expired - Fee Related JP7000162B2 (ja) | 2015-06-09 | 2016-06-09 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501559B2 (https=) |
| EP (1) | EP3307319A4 (https=) |
| JP (2) | JP7000162B2 (https=) |
| KR (1) | KR20180023949A (https=) |
| CN (1) | CN108289950B (https=) |
| AU (1) | AU2016274767B2 (https=) |
| CA (1) | CA2988768A1 (https=) |
| HK (1) | HK1252653A1 (https=) |
| IL (2) | IL281396B (https=) |
| MX (1) | MX2017015666A (https=) |
| SG (1) | SG10202110887PA (https=) |
| WO (1) | WO2016201124A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
| AU2016274767B2 (en) | 2015-06-09 | 2022-05-19 | Eureka Therapeutics, Inc. | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| JP7538601B2 (ja) | 2017-04-26 | 2024-08-22 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| AU2018269370B2 (en) | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| CN112041432A (zh) | 2018-02-15 | 2020-12-04 | 纪念斯隆-凯特林癌症中心 | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 |
| WO2019201995A1 (en) | 2018-04-20 | 2019-10-24 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
| CN113423724B (zh) * | 2018-12-27 | 2023-11-24 | 深圳华大生命科学研究院 | Ebv表位高亲和力t细胞受体 |
| US12084500B2 (en) * | 2019-01-23 | 2024-09-10 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
| WO2020160189A1 (en) * | 2019-01-29 | 2020-08-06 | Gritstone Oncology, Inc. | Multispecific binding proteins |
| GB201901306D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| WO2020191365A1 (en) * | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| JP7674278B2 (ja) | 2019-07-03 | 2025-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 |
| EP3786178A1 (en) * | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| WO2021046331A1 (en) * | 2019-09-05 | 2021-03-11 | Memorial Sloan Kettering Cancer Center | Anti-steap1 antibodies and uses thereof |
| WO2021211455A1 (en) * | 2020-04-13 | 2021-10-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against lmp2 |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| CN111690617B (zh) * | 2020-05-18 | 2023-05-02 | 李欣 | 抗eb病毒lmp2a的单克隆抗体及其细胞株和应用 |
| CN114457165A (zh) * | 2022-04-13 | 2022-05-10 | 深圳荻硕贝肯精准医学有限公司 | 一种用于检测hla-a02基因的引物探针组、试剂盒及检测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68928427T2 (de) | 1988-09-15 | 1998-06-04 | Univ Columbia | Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1998034957A1 (en) | 1997-02-11 | 1998-08-13 | Immunomedics, Inc. | STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| JP2003514871A (ja) | 1999-11-24 | 2003-04-22 | オクラホマ メディカル リサーチ ファウンデーション | 潜伏ウイルス感染についてのアッセイおよび治療 |
| IL151860A0 (en) | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20070048329A1 (en) * | 2002-11-07 | 2007-03-01 | Rajiv Khanna | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| CA2776143A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CN102812043A (zh) * | 2009-11-19 | 2012-12-05 | 新加坡国立大学 | 用于制备t细胞受体样单克隆抗体的方法及其用途 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2673300B1 (en) | 2011-02-11 | 2016-08-24 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
| MX2013011363A (es) | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| LT3030581T (lt) | 2013-08-07 | 2021-05-25 | Affimed Gmbh | Antikūno surišimo vietos specifiškos egfrviii |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| WO2015199618A1 (en) | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| AU2016274767B2 (en) | 2015-06-09 | 2022-05-19 | Eureka Therapeutics, Inc. | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA |
-
2016
- 2016-06-09 AU AU2016274767A patent/AU2016274767B2/en not_active Ceased
- 2016-06-09 EP EP16808304.6A patent/EP3307319A4/en not_active Withdrawn
- 2016-06-09 US US15/735,133 patent/US10501559B2/en active Active
- 2016-06-09 KR KR1020187000659A patent/KR20180023949A/ko not_active Ceased
- 2016-06-09 SG SG10202110887PA patent/SG10202110887PA/en unknown
- 2016-06-09 CN CN201680046924.2A patent/CN108289950B/zh not_active Expired - Fee Related
- 2016-06-09 JP JP2017564407A patent/JP7000162B2/ja not_active Expired - Fee Related
- 2016-06-09 CA CA2988768A patent/CA2988768A1/en active Pending
- 2016-06-09 WO PCT/US2016/036735 patent/WO2016201124A2/en not_active Ceased
- 2016-06-09 IL IL281396A patent/IL281396B/en unknown
- 2016-06-09 HK HK18111960.3A patent/HK1252653A1/zh unknown
- 2016-06-09 MX MX2017015666A patent/MX2017015666A/es unknown
-
2017
- 2017-11-30 IL IL256035A patent/IL256035A/en unknown
-
2019
- 2019-10-28 US US16/665,708 patent/US11168150B2/en active Active
-
2021
- 2021-05-06 JP JP2021078441A patent/JP2021106623A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520667A5 (https=) | ||
| JP7328658B2 (ja) | 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| CN108064236B (zh) | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 | |
| CN110678484B (zh) | 抗pd-l1/抗lag3双特异性抗体及其用途 | |
| KR102701479B1 (ko) | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 | |
| JP2023551027A5 (https=) | ||
| JP2017537082A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| BRPI0611194B1 (pt) | Moléculas de ligação anti-cd16 | |
| JP2020513791A5 (https=) | ||
| JP2017526370A5 (https=) | ||
| CN109715661B (zh) | 抗干扰素-γ的抗体及其应用 | |
| JP2012501670A5 (https=) | ||
| KR20130010117A (ko) | Ｂ７―ｈ３에 반응성인 항체, 면역학적으로 활성인 이들의 단편 및 이들의 사용법 | |
| JP2019515648A (ja) | ＩＬ７受容体細胞外ドメインα鎖に対する非拮抗性抗体及び癌治療におけるそれらの使用 | |
| Staelens et al. | Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains | |
| JP2016518333A5 (https=) | ||
| AU2015336931B2 (en) | CD83 binding proteins and uses thereof | |
| CA3227160A1 (en) | Anti-hla-g antibodies | |
| JP2024516098A5 (https=) | ||
| JP2016529213A5 (https=) | ||
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| Loyau et al. | Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity | |
| JP2025528835A5 (https=) |